Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v20-EN | Version v15-FR | |
|---|---|---|
| Language | English | French |
| Date Updated | 2020-06-05 | 2020-01-10 |
| Drug Identification Number | 02368676 | 02368676 |
| Brand name | TRIESENCE | TRIESENCE |
| Common or Proper name | TRIESENCE 1ML SUSP X12 | TRIESENCE 1ML SUSP X12 |
| Company Name | NOVARTIS PHARMACEUTICALS CANADA INC | NOVARTIS PHARMACEUTICALS CANADA INC |
| Ingredients | TRIAMCINOLONE ACETONIDE | TRIAMCINOLONE ACETONIDE |
| Strength(s) | 40MG | 40MG |
| Dosage form(s) | SUSPENSION | SUSPENSION |
| Route of administration | INTRAVITREAL | INTRAVITREAL |
| Packaging size | 12 | 12 |
| ATC code | S01BA | S01BA |
| ATC description | ANTIINFLAMMATORY AGENTS | ANTIINFLAMMATORY AGENTS |
| Reason for shortage | Other (Please describe in comments) | Delay in shipping of the drug. |
| Anticipated start date | 2019-06-03 | 2019-06-03 |
| Actual start date | 2019-05-27 | 2019-05-27 |
| Estimated end date | 2020-09-30 | 2020-06-30 |
| Actual end date | ||
| Shortage status | Actual shortage | Actual shortage |
| Tier 3 Status | No | No |
| Company comments | Production constraints limit product availability; limited stock being distributed upon receipt. | |
| Health Canada comments |